Skip to content

Clinical trials

Carcinoma, Non-Small-Cell Lung trials in China with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Carcinoma, Non-Small-Cell Lung Status: Unknown status Country / region: China Clear all

484 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20062
20073
20083
20099
201012
201113
201217
201321
201419
201524
201642
201726
201841
201949
202053
202157
202247
202335
202410

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status484

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Sun Yat-sen University34
Betta Pharmaceuticals Co., Ltd.18
Tianjin Medical University Cancer Institute and Hospital17
Fudan University15
The First Affiliated Hospital of Guangzhou Medical University12
Zhejiang Cancer Hospital11
Hunan Province Tumor Hospital10
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.9
Shanghai Chest Hospital9
Guangdong Association of Clinical Trials8

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma, Non-Small-Cell Lung484
Lung Neoplasms41
Brain Neoplasms21
Carcinoma7
Colorectal Neoplasms7
Adenocarcinoma of Lung6
Bronchial Neoplasms6
Breast Neoplasms5
Carcinoma, Bronchogenic5
Lung Diseases5

Trials

Showing 1 to 25 of 484. Each trial links to its page on Pharma Observatory.

384 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.